Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
VRDN holding history
Viridian Therapeutics, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
VRDN overviewAll 13F holders of VRDNFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −269,587−100.0% | Sold out | Holders |
| Q1 2026 | 269,587 | $5.27M | <0.1% | −1,106,152−80.4% | Reduced | Holders |
| Q4 2025 | 1,375,739 | $42.8M | <0.1% | +506,551+58.3% | Added | Holders |
| Q3 2025 | 869,188 | $18.8M | <0.1% | −338,683−28.0% | Reduced | Holders |
| Q2 2025 | 1,207,871 | $16.9M | <0.1% | +123,831+11.4% | Added | Holders |
| Q1 2025 | 1,084,040 | $14.6M | <0.1% | +1,084,040 | New | Holders |
| Q4 2024 | 0 | $0 | 0.0% | −684,799−100.0% | Sold out | Holders |
| Q3 2024 | 684,799 | $15.6M | <0.1% | +611,825+838.4% | Added | Holders |
| Q2 2024 | 72,974 | $949.4K | <0.1% | −5,727−7.3% | Reduced | Holders |
| Q1 2024 | 78,701 | $1.38M | <0.1% | −222,588−73.9% | Reduced | Holders |
| Q4 2023 | 301,289 | $6.56M | <0.1% | −661,204−68.7% | Reduced | Holders |
| Q3 2023 | 962,493 | $14.8M | <0.1% | +311,314+47.8% | Added | Holders |
| Q2 2023 | 651,179 | $15.5M | <0.1% | +21,859+3.5% | Added | Holders |
| Q1 2023 | 629,320 | $16.0M | <0.1% | +17,863+2.9% | Added | Holders |
| Q4 2022 | 611,457 | $17.9M | <0.1% | +2,795+0.5% | Added | Holders |
| Q3 2022 | 608,662 | $12.5M | <0.1% | +163,863+36.8% | Added | Holders |
| Q2 2022 | 444,799 | $5.14M | <0.1% | +427,236+2,432.6% | Added | Holders |
| Q1 2022 | 17,563 | $326.0K | <0.1% | −70,842−80.1% | Reduced | Holders |
| Q4 2021 | 88,405 | $1.75M | <0.1% | +88,405 | New | Holders |